We’re excited to highlight a recent publication from the lab of Nine Diagnostics co-founder Daniel Heller: “Machine perception liquid biopsy identifies brain tumours via systemic immune and tumour microenvironment signature,” published in Nature Nanotechnology (December 2025).
This work introduces a new paradigm for liquid biopsy, using nanosensor-derived signals combined with machine learning to detect brain tumors from blood. Rather than relying on predefined biomarkers, the method captures complex, system-level molecular patterns reflecting both tumor biology and the host immune response.
This approach is directly aligned with the core platform we are building at Nine Diagnostics. It reinforces the potential for biomarker-agnostic diagnostics in oncology, particularly for early detection and treatment monitoring in cancers where traditional biomarkers remain limited.